Monica Margoni

Monica Margoni

MD Neurologist PhD in Neuroscience

About

38
Publications
5,951
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
195
Citations
Additional affiliations
September 2020 - present
San Raffaele Scientific Institute
Position
  • Research Associate
October 2018 - present
University of Padova
Position
  • PhD Student
January 2018 - July 2018
Icahn School of Medicine at Mount Sinai
Position
  • Research Associate

Publications

Publications (38)
Article
Background: Natalizumab (NAT) has a strong impact on disease activity of aggressive pediatric multiple sclerosis (MS), with no difference in safety profile compared to adult MS. However, available data are limited by short follow-up. Our aim was to report long-term follow-up data (up to 11 years) of a large Italian pediatric MS cohort treated with...
Article
Full-text available
Background and objectives: Microglia, the resident immune cell of the brain and retina, is widespread activated in the white and gray matter (GM) in multiple sclerosis (MS). The objective of this study is to evaluate the presence and number of hyperreflecting foci (HRF), considered clusters of activated and proliferating retinal microglia, and the...
Article
Full-text available
Multiple sclerosis (MS) is a chronic inflammatory, demyelinating, and neurodegenerative disease affecting the central nervous system, often characterized by the accumulation of irreversible clinical disability over time. In recent years, there has been a dramatic evolution in several key concepts of MS treatment. The demonstration of the effects of...
Article
Objectives: To evaluate white matter and grey matter T1-weighted (w)/T2w ratio (T1w/T2w ratio) in healthy controls and patients with multiple sclerosis, and its association with clinical disability. Methods: In this cross-sectional study, 270 healthy controls and 434 patients with multiple sclerosis were retrospectively selected from 7 European...
Article
Introduction: Pediatric-onset (PO) multiple sclerosis (MS) accounts for about 2-10% of the total MS cases. Recently, a greater attention has been given to POMS, with substantial improvements in the understanding of its pathophysiology, in the diagnostic work-up and in the identification of reliable prognosticators associated with long-term disabil...
Article
Full-text available
Multiple sclerosis (MS) is a chronic inflammatory, demyelinating and neurodegenerative disease affecting the central nervous system (CNS), often characterized by the accumulation of irreversible clinical disability over time. During last years, there has been a dramatic evolution in several key concepts of immune pathophysiology of MS and in the tr...
Article
Background. Neurodegeneration is a major contributor of neurological disability in multiple sclerosis (MS). The possibility to fully characterize normal appearing white matter (NAWM) damage could provide the missing information needed to clarify the mechanism beyond disability progression. Objective. In the present study we aimed to characterize t...
Article
Objective Alemtuzumab-induced autoimmune thyroid events (AIATEs) are the most common adverse effects observed in relapsing-remitting multiple sclerosis (RRMS) patients. This study aims to explore the clinical and biochemical characteristics of such AIATEs, and to examine the risk factors for their occurrence, particularly for the worst clinical phe...
Article
Background cerebellar damage is a valuable predictor of disability, particularly in progressive multiple sclerosis (MS). It is not clear if it could be an equally useful predictor of motor disability worsening in the relapsing-remitting phenotype. Methods cerebellar lesion loads and volumes were estimated on baseline MRI scan from the CombiRx tria...
Article
Full-text available
Background: Although cognition in multiple sclerosis (MS) is assessed by means of several neuropsychological tests, only a few tools exist to investigate patients' perspectives on cognitive functioning. Objective: To develop a new questionnaire aimed at exploring patients' self-perception with respect to cognition in Italian MS patients. Methods: A...
Article
Full-text available
Treatment of pediatric-onset multiple sclerosis (POMS) has been tailored after observational studies and data obtained from clinical trials in adult-onset multiple sclerosis (AOMS) patients. There are an increasing number of new therapeutic agents for AOMS, and many will be formally studied for use also in POMS. However, there are important efficac...
Article
Full-text available
COVER ILLUSTRATION Brain MRI showed red nucleus (RN) atrophy in multiple sclerosis patients since the early stage of the disease. RN atrophy associated with cerebellar and midbrain white matter lesion volume and selective cerebellar lobule atrophy. Furthermore, RN volume correlated with the cerebellar functional system score of the Expanded Disabil...
Article
Full-text available
No study has investigated red nucleus (RN) atrophy in multiple sclerosis (MS) despite cerebellum and its connections are elective sites of MS-related pathology. In this study, we explore RN atrophy in early MS phases and its association with cerebellar damage (focal lesions and atrophy) and physical disability. Thirty-seven relapse-onset MS (RMS) p...
Article
Full-text available
In their recent review, Hacohen et al. 1 have highlighted two major questions in treating paediatric onset multiple sclerosis (POMS): (1) are first-line disease-modifying therapies still an optimal option for children/teens? (2) are highly effective second-line immunosuppressive therapies safe in POMS, especially during a viral pandemic? The author...
Article
Full-text available
Background No data are available on the occurrence of gray matter lesions (GML) in the cerebellum of pediatric multiple sclerosis (pedMS).Objectives We analyzed frequency, number and topography of GML, and their correlation with cerebellar-related disability in pedMS at clinical onset.Methods Fifteen adolescents with pedMS (12F/3M; mean age 14.9 ±...
Article
Full-text available
Cerebellar dysfunctions have been associated to depressive disorders and cognitive impairment in neurodegenerative diseases. The objective is to analyze the associations between cerebellar atrophy, depression, and fatigue in the early phases of relapse-onset multiple sclerosis (RRMS). Sixty-one RRMS patients and 50 healthy controls (HC) were enroll...
Article
Full-text available
Background Pediatric-onset multiple sclerosis (POMS) is characterized by high inflammatory activity, aggressive course and early development of physical and cognitive disability. A highly effective early treatment must be considered in POMS. Objective To evaluate safety and efficacy of natalizumab (NTZ) in naïve POMS. Methods 20 naïve POMS (13F,...
Article
We describe the case of a man with a very-late onset neuromyelitis optica spectrum disorder syndrome (NMOSD) who was initially diagnosed as recurrent antiphospholipid syndrome-associated myelitis. This case illustrates that a puzzle of autoreactive antibodies can be detected in patients having neurological syndromes belonging to the NMOSD. Prompt i...
Article
Full-text available
We evaluated the occurrence of infusion-associated reactions, severe adverse events and no evidence of disease activity 3 status of a therapeutic course consisting of natalizumab followed by alemtuzumab in paediatric-onset multiple sclerosis. Five paediatric-onset multiple sclerosis (age range 16–17 years) were followed for a median of 3.9 years (i...
Article
Full-text available
Background Diffuse white matter (WM) injury is prominent in primary progressive multiple sclerosis (PP‐MS) pathology and is a potential biomarker of disease progression. Diffusion Kurtosis Imaging (DKI) allows the quantification of non‐Gaussian water diffusion, providing metrics with high WM pathological specificity. Objective To characterize the...
Article
Imaging markers for monitoring disease progression in progressive multiple sclerosis (PMS) are scarce, thereby limiting the possibility to monitor disease evolution and to test effective treatments in clinical trials. Advanced imaging techniques that have the advantage of metrics with increased sensitivity to short-term tissue changes and increased...
Article
Full-text available
Background Progressive brain atrophy is a major feature of multiple sclerosis (MS) pathology and is actually considered a major determinant of the progressive accumulation of physical and cognitive disability in MS patients. Although brain atrophy may have different pathological substrates, several lines of evidence suggest that in disease modifyin...
Article
Background: Few data are available on very long-term follow-up of pediatric multiple sclerosis (MS) patients treated with disease modifying treatments (DMTs). Objectives: To present a long-term follow-up of a cohort of Pediatric-MS patients starting injectable first-line agents. Methods: Data regarding treatments, annualized relapse rate (ARR)...
Article
Full-text available
The clinical significance of Virchow Robin spaces (VRS) in inflammatory brain disorders, especially in multiple sclerosis (MS), is still undefined. We analysed enlarged VRS (eVRS) by means of phase sensitive inversion recovery (PSIR) MRI sequence and investigated their association with inflammation or brain atrophy, and to clinical or physical disa...
Article
X-linked adrenoleukodystrophy (X-ALD) is the most common peroxisomal disorder. The disease is the consequence of mutations in the ABCD1 gene that encodes the peroxisomal membrane protein ALDP which is involved in the transmembrane transport of very long-chain fatty acids. We describe a family with six members carrying a novel heterozygous mutation...

Questions

Question (1)
Question
Hi there,
does anybody know about an atlas where I can find the putamen parcellation?
Thanks in advance

Network

Cited By